Imatinib

Better Known as: Gleevec

• Marketed By: Novartis
• Major Indication: Chronic Myelogenous Leukemia and Gastrointestinal Stromal Tumors
• Drug Class: Receptor Tyrosine Kinase (Especially PDGFR, BCR-Abl & KIT) Inhibitor
• Date of FDA Approval (Expiration): 2001 (2015)
• 2009 Global Sales: $3.9 Billion
• Importance: It is one of the best selling cancer drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. It is very specific receptor tyrosine kinase (RTK) inhibitor, binding to Abl, PDGFR and KIT with far greater specificity than other RTKs, helping explain its relatively low impact side effect profile. Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.^[1]
• See Pharmaceutical Drugs for more information about other drugs and disorders

Mechanism of Action

Chronic Myelogenous Leukemia (CML) results from a gene defect in a haematological stem cell, . Compared to the tightly regulated c-Abl kinase, BCR-Abl has a truncated auto-regulatory domain, leading to constitutive activation of its tyrosine kinase activity. The result of this nearly limitless activation is unregulated phosphorylation of downstream receptors leading to uncontrolled growth and survival of leukemic cells. Like many other receptor tyrosine kinases, BCR-Abl is at an equilibrium between two states, an active state and an auto-regulated inactive state. Imatinib functions by binding in the ATP binding site and stabilizing the inactive conformation of BCR-Abl, in which the well known (). A critically important residue, Thr 315, is known as . In the inactive DFG out conformation, and the loops back over the top of the protein . It is this Thr 315 that is believed to give Imatinib its remarkable binding specificity. Although the DFG-out conformation has been seen in other kinases like B-Raf, p38, KDR, Flt-3, and insulin receptor kinase, Imatinib does not bind any of these kinases. The primary reason is appears to be that all of these kinases have a residue at position 315 that is larger than the threonine present in BCR-Abl. These larger residues block the pocket formed by the DFG out conformation in which Imatinib binds, preventing Imatinib from stabilizing these compounds.^[2] Interestingly, both KIT and PDGFR have nearly identical DFG out conformations and have the same Thr residue at this gatekeeper position, explaining how Imatinib binds and inhibits these proteins commonly involved in Gastrointestinal Stromal Tumors. Imatinib resistant forms of BCR-Abl often have mutations at this gatekeeper position, the most prominent being T315I.^[3] In BCR-Abl, by H-bonds to residues Met 318, Thr 315, Glu 286, Asp 381, Ile 380 & His 361 along with hydrophobic interactions with residues Ile 360, Ala 380, Met 290, Val 299, Lys 271, Ala 269, Val 256, & Phe 317 firmly securing the inhibitor in place and stabilizing the inhibited conformation of the kinase.^[4]

To see of key structural elements Click: , , & the .

Pharmacokinetics